What is the Role of HTA for Biosimilars?

Abstract

This Briefing contains a summary of the main points and conclusions from a roundtable organised and facilitated by the Office of Health Economics, together with a summary of the briefing material provided to the participants. The Roundtable was funded by an unrestricted research grant from Amgen. The views reproduced here are the authors’ synthesis of the discussions at the Roundtable (in which they participated). Accordingly, the arguments and views presented in the text, unless stated otherwise, cannot be attributed to any one of the Roundtable participants or to them all collectively. Any recommendations offered by the authors are their own and do not represent the views of the Roundtable participants. The authors are grateful for the comments received by Virginia Acha, Martin Buxton, Emir Cevro, Julia Earnshaw and Arran Shearer on earlier drafts. A first draft of this Briefing was shared with the participants of the Roundtable, who had the opportunity to comment on it. Their feedback was then incorporated in the final version. All errors and omissions remain the responsibility of the two authors.